Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma with germline DDR mutations
2020-002949-42Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chlorambucil in pancreatic adenocarcinoma (PDAC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: 6-month progression-free survival (PFS-6). Started May 2021; status: terminated.
02
Drugs
chlorambucil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2020-002949-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002949-42.